UNSPSC 51283302: Eperezolid

This classification denotes an antibiotic with the molecular formula C18H23FN4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C460ZSU1OW, chemically known as acetamide, n-((3-(3-fluoro-4-(4-(hydroxyacetyl)-1-piperazynyl)phenyl)- 2-oxo-5-oxazolidinyl)methyl)-, (s)- but generally known as eperezolid, which bears US NIH Compound Identifier 73214. European Medicines Agency schedules Eperezolid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06559MIG.

UNSPSC 51283302 Eperezolid is a Commodity code that nominally identifies a specific antibiotic product, but recent state and local solicitations tagged under this code show no activity actually procuring eperezolid itself. Instead, the opportunities clustered here span pharmaceutical procurement more broadly — generic multi-source drugs, over-the-counter products, naloxone, and pharmacy benefit program design. The code appears to be a misclassification artifact in state and local procurement systems, with issuing bodies using it as a catch-all for pharma-related buys rather than as a marker for the specific drug named in the taxonomy.

State and local purchasing offices, health and human services agencies, municipal fire departments, and cooperative purchasing alliances are the issuing bodies active under this code's recent postings. Geographic activity centers on Minnesota and Florida, with Texas HHS also posting. Representative recent opportunities include Seminole County, Florida's IFB for naloxone and drug deactivation systems (due July 26, 2023), the City of Tampa Fire Department's IFB for medical and first aid supplies on an estimated $700,000 contract with SLBE set-asides (due March 13, 2026), the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026), and the Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026). The code's actual procurement activity does not align with its pharmaceutical taxonomy designation, signaling that firms relying on UNSPSC filtering for eperezolid-specific opportunities will find limited relevance here.